Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program.

Fiche publication

Date publication

août 2023

Journal

Scientific reports

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DABAKUYO-YONLI Sandrine , Dr LADOIRE Sylvain

Tous les auteurs :
de Moura A, Vuagnat P, Renouf B, Pierga JY, Loirat D, Vaflard P, Lafayolle de la Bruyère C, Chaumard-Billotey N, Hajjaji N, Ladoire S, Dabakuyo S, Patsouris A, Frenel JS, Nicolai V, Alexandre M, Dohollou N, Grenier J, Bourien H, Bidard FC

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37596388

Résumé

Following the results of the IMpassion130 trial, an early access program (EAP) was opened in France, allowing patients with PD-L1-positive advanced triple negative breast cancer (aTNBC) to receive a combination of paclitaxel and atezolizumab as first line therapy. This EAP was later discontinued when the IMpassion131 trial read out with negative results. We performed a retrospective multicentric analysis in patients who were prospectively enrolled in the French EAP. Efficacy and toxicity data were obtained on 64 patients treated from August 2019 to August 2020 in 10 French cancer centers. Median progression-free survival (PFS) and overall survival (OS) were 4.1 months (95% CI [3.0-5.8]) and 17.9 months (95% CI [12.4-NR]), respectively. The 6-months PFS rate was 28% (95% CI [16-40%]) (N = 18/64), while N = 33/64 patients (52%, 95% CI [38-63%]) experienced a tumor response. Exploratory subgroup analyses retrieved that corticosteroid use at inclusion in the EAP, before treatment initiation, was the only independent unfavorable prognostic factor for PFS (HR 2.7, 95% CI [1.3-5.6]). No new safety signal was observed. This real-life study, unique by its setting (EAP granted by anticipation and later withdrawn), suggests atezolizumab and paclitaxel has a limited efficacy in PD-L1-positive aTNBC, especially in patients receiving corticosteroids as comedication before treatment start.